IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.889
AS - Asia 869
EU - Europa 747
SA - Sud America 272
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 3
Totale 4.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.834
SG - Singapore 454
BR - Brasile 247
CN - Cina 238
FI - Finlandia 177
IT - Italia 131
IE - Irlanda 110
DE - Germania 82
NG - Nigeria 64
NL - Olanda 48
CA - Canada 44
FR - Francia 39
GB - Regno Unito 38
IN - India 38
SE - Svezia 38
HK - Hong Kong 27
JP - Giappone 19
BE - Belgio 18
BD - Bangladesh 15
TR - Turchia 15
CZ - Repubblica Ceca 11
AR - Argentina 9
RU - Federazione Russa 9
CL - Cile 8
IL - Israele 8
UZ - Uzbekistan 8
EG - Egitto 7
AT - Austria 6
IR - Iran 6
MX - Messico 6
PK - Pakistan 6
PL - Polonia 6
ES - Italia 5
EU - Europa 5
IQ - Iraq 5
PT - Portogallo 5
ZA - Sudafrica 5
KR - Corea 4
UA - Ucraina 4
VN - Vietnam 4
AU - Australia 3
KG - Kirghizistan 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DK - Danimarca 2
EC - Ecuador 2
HN - Honduras 2
HU - Ungheria 2
ID - Indonesia 2
JM - Giamaica 2
MA - Marocco 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
DM - Dominica 1
DZ - Algeria 1
GE - Georgia 1
HR - Croazia 1
IM - Isola di Man 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
PH - Filippine 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.871
Salva come PNG Salva come JPEG
Città #
Chandler 516
Wilmington 409
Singapore 196
Shanghai 181
The Dalles 180
Helsinki 176
San Mateo 162
Ashburn 141
Ann Arbor 131
Dublin 109
Boardman 97
New York 87
Lawrence 82
Princeton 82
Leawood 77
Benin City 64
Milan 49
Amsterdam 43
Paris 38
Phoenix 36
Woodbridge 30
Seattle 26
Fairfield 22
London 21
Los Angeles 18
Pune 18
Santa Clara 18
São Paulo 17
Toronto 17
Brussels 16
San Diego 15
Munich 13
Hong Kong 12
Montreal 10
Kocaeli 9
Naples 9
Abbiategrasso 8
Andover 7
Norwalk 7
Rio de Janeiro 7
Tashkent 7
Belo Horizonte 6
Brno 6
Monmouth Junction 6
Porto Alegre 6
Redwood City 6
Salvador 6
Warsaw 6
Cairo 5
Chicago 5
Columbus 5
Redmond 5
Umeda 5
Atlanta 4
Beijing 4
Brasília 4
Dhaka 4
Falls Church 4
Johannesburg 4
Porto 4
Raleigh 4
Reston 4
Shenzhen 4
Tai Kok Tsui 4
Winnipeg 4
Baghdad 3
Bishkek 3
Brooklyn 3
Council Bluffs 3
Dallas 3
Falkenstein 3
Florence 3
Guangzhou 3
Hanover 3
Istanbul 3
Jeddah 3
Pelotas 3
Petrópolis 3
Ribeirão Preto 3
Rome 3
Sacramento 3
San Francisco 3
Tokyo 3
Verona 3
Aparecida de Goiânia 2
Ariano nel Polesine 2
Baku 2
Berazategui 2
Budapest 2
Buenos Aires 2
Canoas 2
Carrara 2
Changsha 2
Changzhou 2
Charleston 2
Charlotte 2
Chennai 2
Clearwater 2
Colombo 2
Cruzeiro 2
Totale 3.367
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 117
Tivantinib for hepatocellular carcinoma 85
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 84
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 80
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 79
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 77
Biomarkers in Hepatocellular Carcinoma-Letter 76
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 76
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 72
COVID-19 and liver cancer clinical trials: not everything is lost 71
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 71
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 71
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 70
Cabozantinib for the treatment of hepatocellular carcinoma 69
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 69
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 69
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 68
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 67
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 66
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 65
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 64
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 63
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 62
Reply to Y. Pointreau et al 62
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 60
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 59
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 59
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 58
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 58
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 57
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 57
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 57
Role of liver biopsy in hepatocellular carcinoma 57
Shaping the landscape of immune oncology in hepatocellular carcinoma 56
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 55
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 55
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 55
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 55
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 54
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 54
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 54
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 53
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 53
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 53
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 52
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 52
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 51
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 51
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 50
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 50
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 50
Regorafenib for the treatment of unresectable hepatocellular carcinoma 49
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 49
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 48
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 46
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 46
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 46
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 46
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 45
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 45
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 45
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 43
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 43
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 43
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 42
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 41
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 41
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 41
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 38
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 38
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 35
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 35
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 34
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 34
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 33
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 32
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 31
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 30
OncoAlert round table discussions: The global COVID-19 experience 30
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 30
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 30
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 30
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 29
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 28
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 28
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 28
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 28
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 26
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 25
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 25
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 24
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 24
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 23
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 23
Response prediction to EGFR-targeted therapies in colorectal cancer 22
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 22
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 22
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 21
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing? 20
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 20
Totale 4.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.893
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021760 3 5 6 4 23 230 118 46 134 95 10 86
2021/2022553 15 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/202690 90 0 0 0 0 0 0 0 0 0 0 0
Totale 5.022